- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02449408
Novel Screening Tools For the Evaluation and Management of Malnourished Children in the Developing World
Study Overview
Status
Detailed Description
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
The investigators plan to recruit 10 overweight or obese adolescents followed by the Duke Division of Pediatric Endocrinology and Diabetes. Investigators will review the electronic medical records of potential participants identified by their primary providers to ensure they meet the eligibility criteria.
The investigators will also recruit 10 infants hospitalized in the Duke Transitional Care Nursery and will review the electronic medical records of potential participants identified by their primary providers to ensure they meet the eligibility criteria.
Description
Inclusion Criteria:
Overweight or Obese: Inclusion criteria for these subjects will include:
- Age 8-17 years;
- male or female; and
- BMI >85% for age.
Premature or Small for Gestational Age: Inclusion criteria for these subjects will include:
- Age <1 year,
- male or female,
- small for gestational age or intra-uterine growth restriction (IUGR) defined by the 9th revision of the International Classification for Diseases OR
- prematurity as defined by the 9th revision of the International Classification for Diseases.
Exclusion Criteria:
- Exclusion criteria include refusal or inability to provide samples of blood.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Overweight or Obese
Children being seen in consultation or follow-up within the Duke Division of Pediatric Endocrinology and Diabetes who are overweight or obese.
|
|
|
Premature or Small for Gestational Age
Infants hospitalized in the Duke Transitional Care Nursery who were born prematurely or small for gestational age.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Variation between results of novel screening tool and standard ELISA
Time Frame: 1 year
|
The 2-D diffusion POCT will be validated against commercial ELISA assays, run in the Duke Molecular Physiology Institute laboratory, using recombinant human leptin and high molecular weight adiponectin from blood samples.
Dose-response curves will be generated using analyte-spiked buffer.
The dose-response data from 20 separate dose-response dilutions will be fit with the five-parameter logistic (5-PL) curve.
The coefficients of variation (inter and intra-assay) for standard ELISAs for leptin and adiponectin assays are less than 10%.
The investigators will analyze the results of each assay in addition to the means and standard deviations of the POCT assays and ELISAs.
The POCT assay will be considered valid if the variation from the ELISA is less than 20% and if there is no statistically significant difference between the means and standard deviations.
|
1 year
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00058058
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Overweight, Obesity, Small for Gestational Age, Prematurity
-
Tel-Aviv Sourasky Medical CenterUnknownSmall for Gestational Age Infants | Appropriate for Gestational Age InfantsIsrael
-
Société des Produits Nestlé (SPN)CompletedSmall for Gestational Age (SGA) Infants | Appropriate for Gestational Age (AGA) InfantsIndia
-
Xiamen Amoytop Biotech Co., Ltd.RecruitingSmall for Gestational AgeChina
-
SandozCompletedSmall for Gestational AgeBelgium, Czechia, Georgia, Hungary, Poland, Romania, Germany
-
PfizerCompletedSmall for Gestational Age
-
Dong-A ST Co., Ltd.CompletedInfant, Small for Gestational AgeKorea, Republic of
-
PfizerCompletedInfant, Small for Gestational AgeCzech Republic, Spain, Sweden, Netherlands, Belgium, France, Germany, Italy, Switzerland
-
GeneScience Pharmaceuticals Co., Ltd.The First Affiliated Hospital with Nanjing Medical University; Tongji Hospital and other collaboratorsUnknownSmall for Gestational Age InfantChina
-
PfizerCompletedSmall For Gestational Age (SGA)Spain
-
Eli Lilly and CompanyCompletedInfant, Small for Gestational AgeGermany